C9142 HCPCS Level II code: Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
CMS terminated C9142: its last date of service was Dec 31, 2022. It stays here for looking up older claims; newer services need a current code.
Official description
C9142Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
Short description: Inj, alymsys, 10 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with C9142 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Statute
- Type of service
- Medical care
- BETOS category
- Other drugs
- Coverage statute
- 1833(t)
- Added
- Oct 1, 2022
- Terminated after
- Dec 31, 2022
Where C9142 sits
- 1C codesOutpatient prospective payment system
- 2Terminated C9142Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code C9142 still valid?
No. CMS terminated C9142; its last date of service was Dec 31, 2022. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover C9142?
CMS lists C9142’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Statute”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside C9142
All C codesC9136Injection, factor viii, fc fusion protein, (recombinant), per i.u.C9137Injection, factor viii (antihemophilic factor, recombinant) pegylated, 1 i.u.C9138Injection, factor viii (antihemophilic factor, recombinant) (nuwiq), 1 i.u.C9139Injection, factor ix, albumin fusion protein (recombinant), idelvion, 1 i.u.C9140Injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u.C9141Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl (jivi), 1 i.u.C9143Cocaine hydrochloride nasal solution (numbrino), 1 mgC9144Injection, bupivacaine (posimir), 1 mgC9145Injection, aprepitant, (aponvie), 1 mgC9146Injection, mirvetuximab soravtansine-gynx, 1 mgC9147Injection, tremelimumab-actl, 1 mgC9148Injection, teclistamab-cqyv, 0.5 mg